Jonathan Palmer

Welcome to another episode of Bloomberg Intelligence's Vanguards of Healthcare podcast, where we speak with the leaders at the forefront of change in the healthcare industry.

My name is Jonathan Palmer, and I'm a healthcare analyst at Bloomberg Intelligence, the in-house research arm of Bloomberg.

I'm thrilled to welcome back Glenn Tullman, the CEO of Transparent, who previously joined us for an episode in April 2023.

Glenn is a titan in this sector.

He's formerly the CEO of Livongo and Allscripts, and he's also the co-founder and a partner of Seven Wire Ventures.

I'm beyond excited to have this opportunity to sit down with him again.

Glenn, welcome back.

Well, why don't we start at a 30,000-foot view with what TransKaren is, and maybe we can cover a little bit what's changed in the last few years since we chatted.

Well, you covered a lot of different pain points and areas of friction.

Maybe you could just talk a little bit about how you're tackling some of those, whether it's quality of care, affordability.

How does the pieces of the puzzle all fit together?

How many members does that work out to these days?

That's a great summary.

You know, if we think back to a couple of years ago, you know, there's been a lot of changes in the marketplace.

Maybe can you give us a lay of the landscape from a from a competitive perspective?

You know, who are you competing with and what is the total market addressable market look like?

Well said.

So if I think about the biggest news since we last talked, it's probably around the Accolade acquisition that happened last year.

Can you maybe talk a little bit about why was Accolade the right choice and what was the catalyst for doing that deal now?

No, it's a new world.